贝康医疗预计2024年收入增41.8%-46.6%
财中社1月13日电贝康医疗-B（02170）发布公告，截止到2024年12月31日的未审计运营数据表明，公司的收入预计在2.95至3.05亿元之间，相较于2023年的2.08亿元，增长幅度约为41.8%至46.6%。收入增长主要得益于多个因素，包括收购新加坡BMX Holdco Pte. Ltd.后利用其全球销售网络推动自主开发产品的国际销售。
此外，公司在2024年成功建立了重要的客户关系，如在北美与Gattaca Genomics LLC签订了销售协议，销售Geri®全时差培养箱；在中国与上海菁华医疗管理股份有限公司签订战略合作协议，涵盖男科检测、胚胎培养及冷藏存储等产品。同时，公司还获得了多项医疗器械注册证书，进一步丰富了产品线，促进了市场渗透率和销售增长。实际财务业绩将在2025年3月发布的业绩公告中确认。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10